ProMIS Neurosciences (PMN) News Today $1.08 -0.07 (-6.09%) (As of 11/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ProMIS Neurosciences presents data from PMN310 Phase1a trialOctober 31, 2024 | markets.businessinsider.comProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease ConferenceOctober 30, 2024 | globenewswire.comProMIS Neurosciences, Inc. (NASDAQ:PMN): Among The 10 Oversold Canadian Stocks to Buy Right NowOctober 24, 2024 | finance.yahoo.comProMIS Neurosciences (NASDAQ:PMN) Stock, Insider Trading ActivityOctober 5, 2024 | benzinga.comProMIS Neurosciences (NASDAQ:PMN) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Buys 60,000 SharesSeptember 25, 2024 | insidertrades.comProMIS Neurosciences Inc PMNSeptember 19, 2024 | morningstar.comProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral NeurosciencesSeptember 12, 2024 | globenewswire.comProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $12,500.00 in StockAugust 17, 2024 | insidertrades.comProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent HighlightsAugust 8, 2024 | markets.businessinsider.comProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024August 1, 2024 | globenewswire.comProMIS Neurosciences regains NASDAQ complianceJuly 31, 2024 | uk.investing.comProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International ConferenceJuly 30, 2024 | globenewswire.comWestwood and Majesticks aiming to dig deeper as LIV Golf heads to JCB ClubJuly 26, 2024 | msn.comProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's TrialJuly 26, 2024 | globenewswire.comProMIS Neurosciences Announces Up to $122.7 Million Private Placement FinancingJuly 26, 2024 | globenewswire.comPMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024May 15, 2024 | msn.comProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent HighlightsMay 14, 2024 | globenewswire.comTrading was temporarily halted for "PMN" at 09:05 AM with a stated reason of "LULD pause." Trading set to resume at 09:05 AM. May 1, 2024 | marketbeat.comProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed AntibodiesApril 30, 2024 | globenewswire.comProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93April 17, 2024 | msn.comProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSApril 9, 2024 | globenewswire.comProMIS Neurosciences to Present in Upcoming Investor Conferences in AprilApril 4, 2024 | globenewswire.comProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsApril 1, 2024 | globenewswire.comProMIS Neurosciences Strengthens Global Intellectual Property PortfolioMarch 11, 2024 | globenewswire.comProMIS Neurosciences to Present at the 2024 BIO CEO & Investor ConferenceFebruary 22, 2024 | globenewswire.comProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein VaccineJanuary 22, 2024 | finance.yahoo.comProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership TransitionJanuary 3, 2024 | finanznachrichten.deBTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)January 3, 2024 | markets.businessinsider.comProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive OfficerJanuary 3, 2024 | markets.businessinsider.comProMIS Neurosciences, Inc. Announces Leadership TransitionJanuary 3, 2024 | finance.yahoo.comProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14November 14, 2023 | msn.comProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 6, 2023 | finance.yahoo.comProMIS Neurosciences scales 31% on $20.4M private placementAugust 22, 2023 | msn.comProMIS Neurosciences Announces $20.4 Million Private Placement FinancingAugust 21, 2023 | finance.yahoo.comTrading was temporarily halted for "PMN" at 09:07 AM with a stated reason of "LULD pause."July 27, 2023 | marketbeat.comTrading was temporarily halted for "PMN" at 09:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comTrading was temporarily halted for "PMN" at 09:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsMay 15, 2023 | finance.yahoo.comClosing Bell: Promis Neurosciences Inc down on Friday (PMN)May 6, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Thursday (PMN)April 27, 2023 | theglobeandmail.comData Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s DiseaseApril 25, 2023 | finance.yahoo.comProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual MeetingApril 24, 2023 | finance.yahoo.comClosing Bell: Promis Neurosciences Inc up on Tuesday (PMN)April 19, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc down on Monday (PMN)April 18, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Friday (PMN)April 15, 2023 | theglobeandmail.comProMIS Neurosciences submits IND application for Alzheimer's treatmentApril 10, 2023 | proactiveinvestors.comTrading was temporarily halted for "PMN" at 09:09 AM with a stated reason of "LULD pause."September 28, 2022 | marketbeat.comTrading was temporarily halted for "PMN" at 10:07 AM with a stated reason of "LULD pause."July 13, 2022 | marketbeat.com Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon knows the truth, which is why they want him silenced (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration. Watch this new documentary and you’ll discover what Elon knows, PMN Media Mentions By Week PMN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMN News Sentiment▼0.000.46▲Average Medical News Sentiment PMN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMN Articles This Week▼20▲PMN Articles Average Week Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CytomX Therapeutics News Milestone Pharmaceuticals News Metagenomi News Adlai Nortye News Cellectar Biosciences News ALX Oncology News Verrica Pharmaceuticals News Spero Therapeutics News Citius Pharmaceuticals News RAPT Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PMN) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.